

(A joint stock limited

pany incorp



Contents

C , A E F A I	2
F A CIA HIGH IGH	4
A AGE E DI C I A DA A I	5
C , A EG E A CE A D HE F A I	31
C IDA ED BA A CE HEE	41
A E C A BA A CE HEE	45
C IDA ED C E A E	49
A E C A C E A E	52
C IDA ED CA HF A E	54
A E C A CA HF A E	57
C IDA ED A E FCHA GE HA EH DE 'E I	59
A E C A A E FCHA GE HA EH DE 'E I	61
E HE F A CIA A E	63
DEF I I	151



rs

1

1

M

1

Corporate Information

40/F, D F C
248 E

H

H

C H I \$ \$

1712-1716, 17 F

H C

133 E

H

C

2120

C

I \$

: (86) 577 3377 1639

F : (86) 577 3373 9117

E : @



F0Hb

F D I ~

	For the six months ended June 30,	
	2024	2023
	(RMB' 000)	(U B'000)
	(Unaudited)	()
\$	828,957	777,925
1	61,513	60,207
1	16,516	11,473
1	44,996	43,729
1	50,724	43,750
1	-5,727	4,979
1	116,536	113,591

	As at		D	~	A~
	June 30, 2024	June 30, 2023			
	(RMB' 000)	(U B'000)			
	(Unaudited)	(A)			
1	3,008,352	3,047,637			
1	1,581,890	1,639,431			
1	1,426,462	1,403,206			
1	1,290,906	1,265,065			
1	135,555	143,141			



Management Discussion and Analysis

D 2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

一、 經 營 業 績 分 析

（一） 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

（二） 經 營 業 績 細 分 析

1. 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

（三） 經 營 業 績 細 分 析

1. 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

Elderly Healthcare Business

A 2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

（一） 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

（二） 經 營 業 績 細 分 析

1. 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

（三） 經 營 業 績 細 分 析

1. 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

（四） 經 營 業 績 細 分 析

1. 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

（五） 經 營 業 績 細 分 析

1. 經 營 業 績 總 體 分 析

2024 年 1 月 1 日 至 2024 年 12 月 31 日 止 的 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 與 2023 年 度 報 告 中 的 經 營 業 績 及 財 務 狀 況 相 比 的 變 化 情 況 及 原 因 分 析 如 下：

Management Discussion and Analysis

I 於 2024, G 2,730 31.1% G B235.1

2022, C H A

G H 2022, C

2021, H C

I J 2024, G C D

2024 《深化醫藥衛生體制改革2024年重點工作任務》,

H

行遠), (固本革新,篤信

H G

Revenue and Cost of Revenue

Management Discussion and Analysis

Revenue and cost of revenue from operating its owned hospitals

Revenue from operating its owned hospitals consists of fees ("Billing Revenue)

	For the six months ended June 30,	
	2024	2023
	(RMB' 000)	(RMB'000)
	(Unaudited)	(Unaudited)
Billing Revenue from owned hospitals	784,892	744,197
Less: Variable considerations	19,256	15,505
Revenue from operating owned hospitals – net	765,636	728,692

For the Reporting Period, the Group’s Billing Revenue from its owned hospitals amounted to RMB784.9 million, representing an increase of 5.5% as compared with that of the same period of 2023, which was mainly due to an increase in treatment and general healthcare services revenue driven by higher outpatient visits and inpatient visits. During the Reporting Period, the variable considerations amounted to RMB19.3 million, representing an increase of RMB3.8 million as compared with that of the same period of 2023, the proportion of the variable considerations to Billing Revenue increased to 2.5% (for the six months ended June 30, 2023: 2.1%).

Management Discussion and Analysis

截至六月三十日止六個月，本公司已錄得虧損為人民幣零元，而去年同期則錄得虧損為人民幣零元。

For the six months ended June 30,
2024 2023
(RMB'000) (RMB'000)
(Unaudited) ()

Management Discussion and Analysis

	For the six months ended June 30, 2024 (Unaudited)	2023 ()
Inpatients	11,648	10,573
Outpatient	2,119,936	1,914,613
(%)	87.4	84.0
Other	1,852,397	1,607,422
(\$ B'000)	586,146	553,572

5 (

Management Discussion and Analysis

Administrative Expenses

D	, \$	G	, \$	G	, \$	For the six months ended June 30,	
						2024	2023
						(RMB'000)	(M B'000)
						(Unaudited)	()
E						64,383	55,922
D						13,955	13,474
C						4,042	14,377
\$						2,199	2,071
						21,692	16,030
Total administrative expenses						106,271	101,924

D , \$ G M B106.3 ,

4.3% 2023, 2023

15.1% 2023. D

71.9% 2023. D

\$ \$ G 13.9%

J 30, 2023: 14.0%).

Management Discussion and Analysis

Finance Expenses – Net

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(M B'000)
	(Unaudited)	()
I	-2,686	-2,705
F	99	-13
B	18,078	14,124
I	5,245	5,053
	2,968	3,151
	761	545
Finance expenses – net	24,465	20,160

D
B4.3
B4.0
G
B24.5
2023,
2023.

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses



Management Discussion and Analysis

Financial Assets

Inventory

As of December 30, 2024, the Company's inventory was RMB51.9 million (as of December 31, 2023: RMB60.6 million), an 14.3% decrease.

Accounts Receivables

As of December 30, 2024, the Company's accounts receivables were RMB443.1 million (as of December 31, 2023: RMB420.4 million), an increase of 5.4%. The Company's accounts receivables turnover ratio was 6.6 times in 2024 (2023: 6.6 times).

As of December 30, 2024, the Company's accounts receivables were RMB443.1 million (as of December 31, 2023: RMB420.4 million), an increase of 5.4%. The Company's accounts receivables turnover ratio was 6.6 times in 2024 (2023: 6.6 times).

Other Receivables and Prepayments

As of December 30, 2024, the Company's other receivables and prepayments were RMB72.3 million (as of December 31, 2023: RMB79.5 million), a 9.1% decrease.

Other Non-current Financial Assets

As of December 30, 2024, the Company's other non-current financial assets were RMB64.3 million (as of December 31, 2023: RMB65.1 million), a 1.2% decrease.

Construction in progress

As of December 30, 2024, the Company's construction in progress was RMB234.0 million (as of December 31, 2023: RMB137.0 million), an increase of 70.8%. The Company's construction in progress was RMB234.0 million (as of December 31, 2023: RMB137.0 million), an increase of 70.8%.

Right-of-use Assets

As of December 30, 2024, the Company's right-of-use assets were RMB170.5 million (as of December 31, 2023: RMB139.1 million), an increase of 22.6%.

Accounts Payables

As of December 30, 2024, the Company's accounts payables were RMB112.5 million (as of December 31, 2023: RMB110.1 million), an increase of 2.2%.

Management Discussion and Analysis

Receipts in Advance and Contract Liabilities

As of June 30, 2024, the amount was RMB26.3 million (December 31, 2023: RMB26.6 million).

Other Payables

As of June 30, 2024, the amount was RMB68.5 million (December 31, 2023: RMB150.3 million).

The breakdown of other payables is as follows:

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Accounts payable	116,536	113,591
Accounts receivable	-112,711	-119,122
Prepaid expenses	-41,660	9,790
Other	-37,934	4,273

Net Cash Generated from Operating Activities

During the six months ended June 30, 2024, the amount was RMB116.5 million (December 31, 2023: RMB111.0 million). The amount was RMB45.0 million (December 31, 2023: RMB5.6 million). The amount was RMB79.4 million (December 31, 2023: RMB42.4 million).

Net Cash Used in Investing Activities

During the six months ended June 30, 2024, the amount was RMB112.7 million (December 31, 2023: RMB111.0 million). The amount was RMB111.0 million (December 31, 2023: RMB111.0 million). The amount was RMB111.0 million (December 31, 2023: RMB111.0 million).

Net Cash Generated from Financing Activities

Significant Investment, Acquisition and Disposal

Bank Borrowings

Contingent Liability

Asset Pledge

Management Discussion and Analysis

Lease Liabilities

As at December 31, 2023, the Group's lease liabilities were \$153.9 million. As at December 31, 2024, the Group's lease liabilities were \$222.8 million. The increase in lease liabilities is primarily due to the recognition of new lease liabilities in the current period.

Financial Instruments

The Group's financial instruments consist of cash and cash equivalents, trade receivables, trade payables, other receivables, other payables, and bank borrowings. The Group's financial instruments are classified as financial assets or financial liabilities.

Exposure to Fluctuation in Exchange Rates

The Group is exposed to fluctuations in exchange rates primarily through its trade receivables and trade payables. The Group's trade receivables are denominated in US dollars, while its trade payables are denominated in Hong Kong dollars. The Group's exposure to fluctuations in exchange rates is managed through the use of foreign exchange derivatives.

Gearing Ratio

The Group's gearing ratio as at December 31, 2024, was 52.6% (December 31, 2023: 53.3%). The gearing ratio is calculated as the ratio of the Group's total debt to its total capitalization.

Employees and Remuneration Policy

As at December 31, 2024, the Group had 4,742 employees (December 31, 2023: 4,765 employees). The Group's remuneration policy is designed to attract and retain talented employees and to reward them for their contributions to the Group's performance. The Group's remuneration policy is based on the employee's position, experience, and performance. The Group's remuneration policy is also influenced by the market conditions and the Group's financial performance.



Management Discussion and Analysis

已 / \$
 I 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。G 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。H 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 C 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。I 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。J 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 醫院股份有限公司 2018 年股權激勵計劃》，(Equity Incentive Scheme)，本公司於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 I 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。J 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。K 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。L 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。M 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。N 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。O 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。P 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。Q 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。R 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。S 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。T 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。U 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。V 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。W 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。X 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。Y 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。
 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。Z 於 2018 年 12 月 31 日，本公司之現金及現金等價物為 \$ 1,000,000。

Management Discussion and Analysis

- (1) 本公司於二零一五年十二月三十一日及二零一六年三月三十一日之資產負債表及損益表，乃根據本公司之會計政策及估計而編製。本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。
- (2) 本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。
- (3) 本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。本公司之會計政策及估計乃根據本公司之業務性質及經營環境而制定。

Management Discussion and Analysis

For the period from January 1, 2021, to June 30, 2024, the company has not issued any shares.

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/Share)	Balance of Incentive Shares		Granted during the Reporting Period	Vested (Unlocked)		Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares	
				Granted but not Vested as at January 1, 2024	Granted and Vested as at January 1, 2024		during the Reporting Period	during the Reporting Period			Granted but not Vested as at June 30, 2024	

D												
Mr. A G	J 18, 2021	J 28, 2022	10.47		243,328							

6-												
Mr. IE	J 18, 2021	J 28, 2022	10.47		4,776							

-												
Mr. (Mr. A G H)	J 18, 2021	J 28, 2022	10.47		23,653							

D J
D JO- 0

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Vesting Date	Grant Price (RMB/ Share)	Balance of	Balance of	Granted during the Reporting Period	Vested	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of
				Incentive Shares Granted but not Vested as at January 1, 2024	Incentive Shares Granted and Vested as at January 1, 2024		(Unlocked) during the Reporting Period			Incentive Shares Granted but not Vested as at June 30, 2024

()

Corporate Governance and Other Information

C A E G E A CE

D \$ ~ ~ CG C .

C M , IA CE I H HE DE C DE

C ~ ~ C ~ ~ C ~ ~ D ~ ~ \$ ~ ~

Corporate Governance and Other Information

[illegible]



Corporate Governance and Other Information

CHAIRMAN OF THE BOARD OF DIRECTORS, CHIEF EXECUTIVE OFFICER, AND AGENT

\$ - - - - - D \$ - - - - - C

EXECUTIVE AFFAIRS, HEAD, GENERAL

\$ - - - - - \$ - - - - - G - - - - -

CHAIRMAN OF THE BOARD OF DIRECTORS, CHIEF EXECUTIVE OFFICER

Corporate Governance and Other Information

Directors', Supervisors' and Chief Executive's Interests in Securities

Directors', Supervisors' and Chief Executive's Interests in Securities

As of December 31, 2024, the interests of Directors, Supervisors and Chief Executive in the Company's securities are as follows:

(1) Mr. Guo Jiajun: 19,350,250 shares of Class D, 3,694,500 shares of Class H, and 100,000 shares of Class J. He also holds 159,100 shares of Class H through the Shanghai Jinzhi Enterprise Management Center (Limited Partnership).

(2) Mr. Guo Jiajun: 19,350,250 shares of Class D, 3,694,500 shares of Class H, and 100,000 shares of Class J. He also holds 159,100 shares of Class H through the Shanghai Jinzhi Enterprise Management Center (Limited Partnership).

(3) Mr. Guo Jiajun: 4,540,000 shares of Class D.

Name of Directors	Class of Shares	Nature of Interest	Number of Shares	Total Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares ⁽¹⁾
Mr. Guo Jiajun ⁽²⁾	D	Direct	19,350,250 ()	22,044,750 ()	39.99%	29.55%
	H	Indirect	3,694,500 ()			
Mr. Guo Jiajun ⁽²⁾	D	Direct	3,694,500 ()	22,044,750 ()	39.99%	29.55%
	H	Indirect	19,350,250 ()			
	H	Indirect	149,300 ()	149,300 ()	0.77%	0.20%
Mr. Guo Jiajun	D	Direct	100,000 ()	100,000 ()	0.13%	0.13%
	H	Indirect	159,100 ()			
Mr. Guo Jiajun ⁽³⁾	D	Direct	4,540,000 ()	4,540,000 ()	3.22%	6.09%

(1) The total number of shares of the Company is 55,260,000. The total number of shares of Class D is 19,340,300. The total number of shares of Class H is 74,600,300. The total number of shares of Class J is 100,000.

(2) Mr. Guo Jiajun is the Chairman of the Board of Directors and the Chairman of the Supervisory Board. He is also the Chairman of the Shanghai Jinzhi Enterprise Management Center (Limited Partnership).

(3) Mr. Guo Jiajun is the Chairman of the Board of Directors and the Chairman of the Supervisory Board. He is also the Chairman of the Shanghai Jinzhi Enterprise Management Center (Limited Partnership).

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
上海金浦健服股權投資管理有限公司 ⁽²⁾	D	~	4,540,000()	3.22%	6.09%
溫州金寧股權投資合夥企業(有限合夥)	D	~ B	4,540,000()	3.22%	6.09%
(6)	D	~	3,934,350()	7.21%	5.34%
上海檀英投資合夥企業(有限合夥)	D	~ B	4,519,003()	3.13%	6.06%
上海樂進投資合夥企業(有限合夥) ⁽³⁾	D	~	4,519,003()	3.13%	6.06%
↓	D	~	6,506,309()	11.77%	3.72%
上海正心谷投資管理有限公司	D	~	6,506,309()	11.77%	3.72%
上海盛歌投資管理有限公司 ⁽⁴⁾					
萬得信息技術股份有限公司	D	~	3,333,000()	6.03%	4.47%
上海荷花緣企業管理中心(有限合夥)	D	~	3,333,000()	6.03%	4.47%

Corporate Governance and Other Information

▼

- ():
- (1) 74,600,300 55,260,000 D 19,340,300 H (30, 2024.
- (2) FA 50% J E C () (上海金浙企業管理中心(有限合墊澄琿

ASSETS		Balance as at the end of the period	B \$
Current assets:			
Cash and cash equivalents	()	373,302,433.47	418,561,721.39
Financial assets at fair value through profit or loss	()	7,599,178.13	7,350,293.53
Derivatives	()	763,849.74	
Accounts receivable	(\$)	448,102,421.02	420,441,069.56
Accounts payable	(\$)	2,366,951.74	9,330,552.93
Prepaid expenses and other receivables	(\$)	69,943,027.66	69,705,723.93
Financial assets at fair value through other comprehensive income	(\$)	51,889,640.76	60,600,130.25
Investments in subsidiaries, associates and joint ventures	(\$)	3,053,787.78	353,020.39
Total current assets		957,021,290.30	937,647,572.03

Consolidated Balance Sheets

June 30, 2024
(Amount in US Dollars)

		Balance as at the end of the period	Balances
ASSETS	Unit		\$
Non-current assets:			
Land use rights			
Patent			
Investment property			
Long-term equity investments	()	14,000,000.00	14,000,000.00
Other non-current assets	()	141,550,815.01	139,071,937.05
Prepaid expenses	()	64,751,652.55	65,099,055.34
Intangible assets	()	782,127,103.00	794,356,342.94
Goodwill	()	234,034,296.61	186,930,240.67
Other non-current assets	(\$)	170,465,125.54	139,054,506.63
Current assets:	(\$)	307,875,476.38	320,321,705.16
Cash and cash equivalents			
Accounts receivable			
Prepaid expenses			
Other current assets	(\$)	119,909,089.24	119,909,039.24
Inventory	(\$)	156,750,581.45	175,910,626.14
Other current assets	(\$)	44,940,518.91	45,146,270.60
Other current assets	()	14,925,823.45	9,639,210.94
Total non-current assets		2,051,330,482.14	2,060,039,034.76
Total assets		3,008,351,772.44	3,047,636,606.34

GUAN Weili

JIN Hui

WANG Minhui

Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

LIABILITIES AND SHAREHOLDERS' EQUITY		Balance as at the end of the period	B \$
Current liabilities:			
()	111,000,000.00	127,001,700.00	
B			
F	()	12,400,000.00	12,400,000.00
D \$ \$			
			1,545,021.09
A	()	112,544,938.03	110,060,007.67
	(\$)	26,157,511.69	26,563,603.06
C	(\$)	92,924.53	
F			
F			
F			
E	(\$)	67,014,464.52	34,324,006.40
	(\$)	30,855,445.81	33,553,746.47
	(\$)	68,487,137.05	150,270,575.15
F			
	()	108,286,381.25	250,411,756.99
	()	569,425.21	
Total current liabilities		537,408,228.09	301,130,416.33
Non-current liabilities:			
\$	()	768,224,669.65	557,719,214.69
B			
I			
	()	158,912,952.10	163,239,532.76
	()	64,227,913.88	61,351,340.53
\$			
D	(\$)	8,582,203.00	3,734,099.00
D	(\$)	44,533,949.56	47,306,056.21
Total non-current liabilities		1,044,481,688.19	333,350,243.19

Consolidated Balance Sheets

June 30, 2024

(Amount in million RMB)

		Balance as at the end of the period	B ¥
LIABILITIES AND SHAREHOLDERS' EQUITY	▼	I	\$

Parent Company Balance Sheets

J 30, 2024

(A B)

		Balance as at the end of the period	B
ASSETS			\$
Current assets:			
C		167,239,404.12	136,337,559.21
F			
D			
A	()	55,989,746.68	43,066,557.69
A		6,900.00	223,131.12
I	()	622,922,583.60	600,443,325.53
I		9,687,901.11	11,131,002.59
I : D			
C			
A			
		355,000.00	330,000.00
Total current assets		856,201,535.51	347,091,576.19

Parent Company Balance Sheets

J 30, 2024

(A B)

	Balance as at the end of the period	B
LIABILITIES AND SHAREHOLDERS' EQUITY		\$
Current liabilities:		
F	111,000,000.00	125,000,000.00
D		
A	37,382,041.07	33,774,329.53
	3,483,707.09	4,172,410.35
C		
E	16,652,661.89	20,572,854.31
	2,812,623.38	1,603,746.33
	42,052,422.61	38,919,608.73
	59,854,608.34	173,615,500.00
Total current liabilities	273,238,064.38	397,658,449.25
Non-current liabilities:		
B	506,300,000.00	362,042,127.25
I		
	16,710,574.36	25,855,234.63
D	8,582,203.00	8,734,099.00
D		
Total non-current liabilities	531,592,777.36	396,631,460.88
Total liabilities	804,830,841.74	794,289,910.13



Parent Company Balance Sheets

June 30, 2024

(Amount in US Dollars)

	Balance as at the end of the period	B \$
LIABILITIES AND SHAREHOLDERS' EQUITY		
Shareholders' equity:		
Capital stock	74,600,300.00	74,600,300.00
Reserves		
Surplus reserve	862,663,919.13	871,230,628.64
Other reserves	3,146,832.71	12,557,011.74
Total reserves		
Other shareholders' equity		
Other equity	38,399,577.13	38,399,577.13
Total shareholders' equity	291,128,201.08	254,123,941.46
Total liabilities and shareholders' equity	1,263,645,164.63	1,255,767,435.49
	2,068,476,006.37	2,050,057,345.62

GUAN Weili JIN Hui WANG Minhui

Consolidated Income Statement

F J 30, 2024

(A B C D E F G H I J K L M N O P Q R S T U V W X Y Z AA AB AC AD AE AF AG AH AI AJ AK AL AM AN AO AP AQ AR AS AT AU AV AW AX AY AZ BA BB BC BD BE BF BG BH BI BJ BK BL BM BN BO BP BQ BR BS BT BU BV BW BX BY BZ CA CB CC CD CE CF CG CH CI CJ

Item	Amount for the current period	Amount for the prior period
I. Total revenue	() 828,957,553.71	777,925,163.84
I : \$	() 828,957,553.71	777,925,163.84
I		
F		
II. Total cost of sales	766,642,937.50	724,044,723.76
I : C	() 602,800,461.11	576,390,595.76
I		
F		
G		
F		
I : I		
I		
G	() 6,268,298.95	2,783,861.65
G	() 9,249,266.44	7,823,610.00
G	() 106,271,383.70	101,924,026.76
F	(\$) 17,588,076.15	14,957,995.63
F	(\$) 24,465,451.15	20,159,633.96
I : I	23,323,466.98	19,182,137.46
I	2,686,209.46	2,704,831.09
A :	(\$) 5,588,263.28	5,522,495.15
I \$	(\$) 1,680,199.57	-195,725.93
I : I \$	478,827.96	-157,522.45
D		
F		
G		
G		
C	(\$) -98,523.19	
A	() -5,584,264.01	-3,009,926.77
G	() -74,985.41	

Consolidated Income Statement

For the six months ended June 30, 2024

(All amounts in RMB Yuan unless otherwise stated)

Item		Amount for the current period	A \$	U.S. -
III. Operating profit (losses represented with "-" sign)		63,825,306.45	56,497,232.53	
A	-	() 503,489.95	5,924,960.95	
B	-	() 2,816,219.76	2,215,131.37	
IV. Total profit (total losses represented with "-" signs)		61,512,576.64	60,207,112.14	
A	-	() 16,516,143.35	11,477,330.07	

Consolidated Income Statement

For the period from January 1, 2024 to June 30, 2024
(Amount in million RMB)

Item	Amount for the current period	A
()		
1.		
2. C		
3. A		
4. C		
5.		
6. E		
7.		
VII. Total comprehensive income	44,996,433.29	43,729,232.07
A	50,723,744.20	43,750,057.46
A	-5,727,310.91	4,979,174.61
VIII. Earnings per share:		
() B (B)	(\$) 0.68	0.59
() D (B)	(\$) 0.68	0.59

-1.57

GUAN Weili JIN Hui WANG Minhui

221.0 17

Parent Company Income Statement

F J 30, 2024
(A B)

Item	Amount for the current period	A
V. Other comprehensive income, net of tax		
()		
1. C		
2.		
3. C		
4. C		
()		
1.		
2. C		
3. A		
4. C		
5.		
6. E		
7.		
VI. Total comprehensive income	29,384,349.62	-3,676,344.29
VII. Earnings per share:		
() B (B)		
() D (B)		

GUAN Weili JIN Hui WANG Minhui



Item	Amount for the current period	A	Y
		\$	¥
I. Cash flows from operating activities			
Cash receipts from sales of goods and services	774,736,897.94	780,036,767.35	
Receipts from government subsidies			
Receipts from interest and dividends			
Receipts from disposal of non-current assets			
Receipts from disposal of subsidiaries			
Receipts from financing activities			
Receipts from operating activities			
Cash payments for operating activities	40,064,567.80	169,903,996.27	
Sub-total of cash inflows of operating activities	814,801,465.74	949,990,763.62	
Cash payments for operating activities	264,247,149.21	279,096,560.43	
Payments for government subsidies			
Payments for interest and dividends			
Payments for disposal of non-current assets			
Payments for disposal of subsidiaries			
Payments for financing activities			
Payments for operating activities	329,971,885.59	300,131,941.56	
Payments for operating activities	40,687,505.65	37,324,192.11	
Payments for operating activities	63,358,941.68	219,346,730.32	
Sub-total of cash outflows of operating activities	698,265,482.13	836,399,424.92	
Net cash flows from operating activities	116,535,983.61	113,591,338.70	

Consolidated Cash Flow Statement

For the six months ended June 30, 2024

(All amounts in RMB Yuan unless otherwise stated)

Item	Amount for the current period	A	↓
		\$	¥
II. Cash flows from investing activities			
C -			8,249,457.77
C -			
▼	644,865.42	26,353.01	
▼	432,733.42		
C -			
C -	1,077,598.84	8,275,840.78	
C -			
	111,001,022.93	107,843,620.41	
C -	2,000,000.00	3,866,900.00	
▼			15,187,013.06
▼			
C -	787,500.00	500,059.94	
	113,788,522.93	127,397,593.41	



Item	Amount for the current period	A \$	¥
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-99,244.67		13,070.04
V. Net increase in cash and cash equivalents	-37,934,050.43	4,272,913.65	
A : C ¥ : \$	404,723,339.37	253,595,990.97	
VI. Cash and cash equivalents at the end of the period	366,789,288.94	262,363,904.62	

GUAN Weili	JIN Hui	WANG Minhui
------------	---------	-------------

Parent Company Cash Flow Statement

For the year ended June 30, 2024

(Amounts in millions of dollars)

Item	Amount for the current period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from customers	178,625,474.28	186,510,657.37
Cash received from other sources	334,259,258.00	491,763,053.70
Sub-total of cash inflows of operating activities	512,884,732.28	678,273,711.07
Cash paid for operating expenses	66,197,024.94	80,195,550.90
Cash paid for income taxes	84,545,764.25	80,391,274.33
Cash paid for interest	2,949,959.92	433,377.67
Cash paid for other operating activities	338,808,072.60	463,041,604.81
Sub-total of cash outflows of operating activities	492,500,821.71	624,567,307.71
Net cash flows from operating activities	20,383,910.57	53,706,403.36
II. Cash flows from investing activities:		
Cash received from the sale of property, plant and equipment		16,657,744.50
Cash received from the sale of investments	13,273,818.98	
Cash paid for the acquisition of property, plant and equipment	10,427.00	
Cash paid for the acquisition of investments		
Cash paid for other investing activities		
Sub-total of cash inflows of investing activities	13,284,245.98	16,657,744.50
Cash paid for the acquisition of property, plant and equipment	1,277,334.63	1,691,749.51
Cash paid for the acquisition of investments	7,200,000.00	29,166,900.00
Cash paid for other investing activities		
Sub-total of cash outflows of investing activities	8,477,334.63	30,858,649.51
Net cash flows from investing activities	4,806,911.35	-14,200,905.01

Parent Company Cash Flow Statement

For the period from January 1, 2024 to December 31, 2024
(Amount in million RMB)

Item	Amount for the current period	A
	\$	¥
III. Cash flows from financing activities:		
Cash received from issuing shares	293,000,000.00	199,050,000.00
Sub-total of cash inflows of financing activities	293,000,000.00	199,050,000.00
Cash paid for acquisition of subsidiaries	276,792,127.25	101,150,000.00
Cash paid for acquisition of intangible assets	35,406,263.84	12,364,450.26
Cash paid for other financing activities	25,472,250.00	79,243,750.00
Sub-total of cash outflows of financing activities	337,670,641.09	192,758,200.26
Net cash flows from financing activities	-44,670,641.09	6,291,799.74
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-119,720.72	13,070.04
V. Net increase in cash and cash equivalents	-19,599,539.89	45,810,373.13
Balance at the beginning of the period	185,475,808.48	90,387,144.89
VI. Cash and cash equivalents at the end of the period	165,876,268.59	136,197,518.02

GUAN Weili

JIN Hui

WANG Minhui

Director

Accounting Director

Director

Chief Financial Officer

Chief Financial Officer

Chief Financial Officer

Consolidated Statement of Changes in Shareholders' Equity

F J 30, 2024

$$(A \quad \begin{smallmatrix} \nearrow & \searrow \\ \nearrow & \searrow \end{smallmatrix} \quad B \quad \begin{smallmatrix} \nearrow & \searrow \\ \nearrow & \searrow \end{smallmatrix})$$

Items	Amount for the current period													
	Equity attributable to owners of the parent company													
	Other equity instruments					Other								
	Share capital	Preferential shares	Perpetual bonds	Others	Capital reserve	Treasury stock	Less: comprehensive income	Special reserves	Surplus reserves	Provision for general risk	Retained earnings	Subtotal	Minority interests	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				882,685,600.69	12,587,011.74			38,393,577.13		311,956,279.16	1,265,064,636.24	143,141,250.58	1,408,205,946.82
II. Balance as at the beginning of the current year	74,600,300.00				882,685,600.69	12,587,011.74			38,393,577.13		311,956,279.16	1,265,064,636.24	143,141,250.58	1,408,205,946.82
III. Increases/decreases in the current period ("+" for increases, "-" for decreases)					-11,942,120.95	-9,440,179.03					28,343,654.20	25,841,722.28	-7,585,802.94	18,255,909.34
(1) C					-8,566,703.51	-9,440,179.03					50,723,744.20	50,723,744.20	-5,727,310.91	44,966,433.29
(2) C					-9,334,383.19	-9,440,179.03						873,683.52	1,033,024.97	1,906,494.49
(3) A												105,795.94	1,033,024.97	1,138,820.91
(4) D					767,673.68							767,673.68		767,673.68
(5) I											-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00
(6) J											-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00

Parent Company Statement of Changes in Shareholders' Equity

F J 30, 2024

$$(A \quad \begin{array}{c} \nearrow \\ \searrow \end{array} \quad B \quad \begin{array}{cc} \nearrow & \searrow \\ \nearrow & \searrow \end{array})$$

Items	Other equity instruments					Amount for the current period					
	Share capital	Preferential shares	Perpetual bonds	Others	Capital reserve	Treasury stock	Less: comprehensive income	Special reserves	Surplus reserves	Retained earnings	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				871,230,628.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
A : C											
C											
II. Balance as at the beginning of the current year	74,600,300.00				871,230,628.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
III. Increases/decreases in the current period ("+" for increases)					-8,566,709.51	-9,440,179.03			7,004,259.62	29,384,349.62	7,877,729.14
()					-8,566,709.51	-9,440,179.03			29,384,349.62		873,469.52
()					-8,566,709.51	-9,440,179.03					105,795.04
1. C					-9,334,383.19	-9,440,179.03					
2. C											
3. A											
4. D					767,673.68						767,673.68
() D											
1. C											
2. C											
3. C											
(\$) I											
1. C											
2. C											
3. C											
4. C											
5. C											
6. C											
(\$)											
1. C											
2. C											
(\$)											
IV. Balance as at the end of the period	74,600,300.00				862,663,919.13	3,146,832.71			38,399,577.13	291,128,291.08	1,263,645,164.63

GUAN Weili

JIN Hui

WANG Minhui

Notes to the Financial Statements

F 30, 2024
(A B)

I. G

H C , . (C) ~ ~ ~ \$
復醫院) F 1996. ~ ~ C (溫州市康寧精神康
D , , C. , H

15, 2014, C \$
H C , . (溫州康寧醫院股份有限公司).

C C ~ ~ E H \$ 20, 2015.
C ~ ~

C ~ \$ ~ C , 33 (C (G 1))25

(I) Basis of preparation

Notes to the Financial Statements

F
(A

II. B (C)

(II) Going concern

(III) Statement of compliance with the Accounting Standards for Business Enterprises

A B E
F C J 30, 2024 J 2024.

III.

(I) Major tax categories and tax rates

Tax categories	Tax basis	Tax rate
(A)	A	

(II) Preferential tax treatment

F J 30, 2024

(A B)



(I) Cash at bank and on hand

Items	Balance as at the end of the period	B \$
C	315,188.51	371,623.69
C	367,196,561.26	416,950,293.93
	5,790,683.70	1,509,793.72
	373,302,433.47	418,561,721.39

(II) Financial assets held for trading

Items	Balance as at the end of the period	B \$
F	7,599,178.13	7,350,293.53
I	7,599,178.13	7,350,293.53
	7,599,178.13	7,350,293.53

(III) Notes receivable

Items	Balance as at the end of the period	B \$	€
B	763,849.74		
	763,849.74		



Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in thousands of RMB)

1. Accounts receivable (Note 1)

(IV) Accounts receivable

1. Aging schedule of accounts receivable

Aging	Balance as at the end of the period	B \$
1	443,637,522.96	425,833,221.01
1-2	42,631,127.19	6,696,709.84
2-3	4,507,504.01	4,430,032.80
3-4	10,140,966.30	7,730,009.57
4-5	500,917,120.46	444,739,973.22
5-6	52,814,699.44	24,343,903.66
	448,102,421.02	420,441,069.56

2. Accounts receivable

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024
(Amount in thousands of RMB)

1. Accounts receivable (Continued)

(IV) Accounts receivable (Continued)

3. Changes in the current period						
Category	Balance at the end of the previous period	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
1. Accounts receivable	12,354,532.25		-11,415,706.28			24,270,288.56
2. Advances to suppliers	11,494,321.35	17,050,089.50				28,544,410.88
	24,348,903.66	17,050,089.50	-11,415,706.28			52,814,699.44

(V) Advances to suppliers

Aging	Balance as at the end of the period		Balance at the end of the period	
	Amount	Proportion (%)	Amount	Proportion (%)
1	2,326,232.07	98.28	9,048,941.15	92.05
1-2			742,811.80	7.56
2-3	7,919.67	0.33	6,000.00	0.06
3	32,800.00	1.39	32,800.00	0.33

Notes to the Financial Statements

For the year ended December 31, 2024

(As per the audited financial statements)

1. (C) (VI) Other receivables

Items	Balance as at the end of the period	B \$
1. / \$	787,500.00	
\$	69,155,527.66	69,705,728.98
	69,943,027.66	69,705,728.98

1. / \$

1. / \$

Items	Balance as at the end of the period	B \$
	787,500.00	
	787,500.00	

2. \$

(1) D \$

Aging	Balance as at the end of the period	B \$
1	50,656,821.58	53,412,990.26
1 2	15,533,337.46	29,894,811.69
2 3	33,706,673.72	8,912,677.15
3 4	1,438,191.47	5,404,423.07
4 5	1,977,221.69	742,744.83
\$ 5	4,436,981.60	3,885,239.68
	107,749,227.52	102,252,886.68
\$	38,593,699.86	32,547,157.70
	69,155,527.66	69,705,728.98



Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

(VI) Other receivables (Continued)

2. (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

(2) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

Category	Balance as at the end of the period					B				
	Book balance		Provision for bad debts		Book value	B		B		B
	Amount	Proportion (%)	Amount	Proportion of provision (%)		A	(%)	A	(%)	
Other receivables	36,761,735.90	34.12	36,761,735.90	100.00	37,404,736.41	36.58	30,697,494.28	92.07	6,707,242.13	
Other receivables	23,066,977.13	21.41	23,066,977.13	100.00	23,709,977.64	23.19	17,002,735.51	71.71	6,707,242.13	
Other receivables	10,204,311.69	9.47	10,204,311.69	100.00	10,204,311.69	9.98	10,204,311.69	100.00		
Other receivables	3,490,447.08	3.24	3,490,447.08	100.00	3,490,447.08	3.41	3,490,447.08	100.00		
Other receivables	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64.98	1,849,663.42	2.95	62,998,446.85	
Other receivables	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64.98	1,849,663.42	2.95	62,998,446.85	
	107,749,227.52	100.00	38,593,699.86		69,155,527.66	102,252,886.68	100.00	32,547,157.70		69,705,728.98

Notes to the Financial Statements

Fiscal year ended June 30, 2024

(Amount in millions of Japanese yen)

1. Other receivables (Continued)

(VI) Other receivables (Continued)

2. Other receivables (Continued)

(2) Other receivables (Continued)

Name	Balance as at the end of the period			B		B	
	Book balance	Provision for bad debts	Proportion of provision (%)	\$	B	\$	B
H							
H C	23,066,977.13	23,066,977.13	100.00	\$	23,709,977.64	17,002,735.51	
H							
C	10,204,311.69	10,204,311.69	100.00	\$	10,204,311.69	10,204,311.69	
C (汪長勝)	3,490,447.08	3,490,447.08	100.00	\$	3,490,447.08	3,490,447.08	
	36,761,735.90	36,761,735.90			37,404,736.41	30,697,494.28	

\$

\$

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
	70,987,491.62	1,831,963.96	2.58
	70,987,491.62	1,831,963.96	

$$(3) \quad D = \begin{array}{c} f \\ \downarrow \\ \text{\scriptsize D} \end{array} \quad \$ = \begin{array}{c} f \\ \downarrow \\ \text{\scriptsize f} \end{array}$$

Notes to the Financial Statements

F J 30, 2024
(A B)

(C)

(VI) Other receivables (Continued)

2. \$(C)

(3) D \$(C)

C \$

Book balance	Stage I	Stage II	Stage III	Total
	12-month ECL	Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
B				
\$	64,843,150.27		37,404,736.41	102,252,886.68
B				
\$				
\$	3,400 () /C00) 9 .0733 D10 ()			

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024
(Amount in million RMB)

1. Other receivables (Continued)

(VI) Other receivables (Continued)

2. Other receivables (Continued)

(4) Other receivables (Continued)

Category	B \$	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
Accounts receivable	30,697,494.28	6,064,241.62				36,761,735.90
Other receivables	1,849,663.42		17,428.98	270.48		1,831,963.96
	32,547,157.70	6,046,241.62	17,428.98	270.48		38,593,699.86

(5) Other receivables (Continued)

	Book balance as at the end of the period	B \$
D	22,840,821.05	22,266,761.49
E	25,289,000.00	19,150,000.00
F	1,583,692.95	4,818,862.51
A	23,134.70	51,045.33
A	51,845,560.25	52,887,698.31
A	2,000,000.00	
A	4,167,018.57	3,078,519.04
	107,749,227.52	102,252,886.68

Notes to the Financial Statements

For the period ended June 30, 2024

(Amounts in millions of US dollars)

(VII) Inventories

		Balance as at the end of the period		B	~	√	\$	~	

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(All amounts in RMB Yuan, unless otherwise specified)

X. Long-term equity investments

Investees	Increase/decrease in the current period						Balance of the impairment provision as at the end of the previous year	Increase/decrease in the current period				Balance of the impairment provision as at the end of the period
	Investment	Decrease in investment	Investment profit/loss recognized under equity method	Other comprehensive income adjustment	Other equity changes	Cash dividends or profits declared and paid		Investment profit/loss recognized under equity method	Other comprehensive income adjustment	Other equity changes	Impairment provision	
A												
H												
C							16,018,884.93	687,659.39				16,706,544.37
H							56,841,432.86	-166,415.53				56,675,017.33
H							21,561,607.67	-393,224.24				21,168,383.43
H												
C							22,287,534.75	712,327.54				22,999,862.29
H							18,649,398.65	-31,479.31				18,617,919.34
F							3,713,128.14	-330,039.89				5,393,088.25
C							2,000,000.00					
							2,000,000.00	478,827.96				141,550,815.01

Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in millions of Philippine pesos)

1. Other non-current financial assets

(XI) Other non-current financial assets

	Balance as at the end of the period	B \$
For the period ended June 30, 2024	64,751,652.55	65,099,055.34
For the period ended June 30, 2023	64,751,652.55	65,099,055.34
	64,751,652.55	65,099,055.34

(XII) Fixed assets

1. Fixed assets

Items	Balance as at the end of the period	B \$
For the period ended June 30, 2024	782,127,103.00	794,356,342.94
For the period ended June 30, 2023	782,127,103.00	794,356,342.94
	782,127,103.00	794,356,342.94

Notes to the Financial Statements

F
(A

(C

(XIII) Construction in progress

1.		C		B		I		C	
		Balance as at the end of the period		B		I		C	
		Book	Impairment	Carrying	B	I		C	
Items		balance	provision	amount			\$		
C		234,034,296.61		234,034,296.61	136,930,240.67			136,930,240.67	
C									
		234,034,296.61		234,034,296.61	136,930,240.67			136,930,240.67	
2.		D		B		I		C	
		Balance as at the end of the period		B		I		C	
		Book	Impairment	Carrying	B	I		C	
Items		balance	provision	amount			\$		
H		137,317,869.97		137,317,869.97	101,029,929.74			101,029,929.74	
C	H	89,526,711.76		89,526,711.76	35,174,600.41			35,174,600.41	
H	C	3,766,450.99		3,766,450.99					
		3,423,263.89		3,423,263.89	775,710.52			775,710.52	



Notes to the Financial Statements

For the period ended December 31, 2024

(Amount in thousands of RMB)

1. Right-of-use assets (C)

(XIV) Right-of-use assets

Items		Buildings and structure	Total
1.	\$ -		
(1) B	-	301,405,111.73	301,405,111.73
(2) I	-	70,403.22	70,403.22
(3) D	-	70,403.22	70,403.22
(4) B	-	1,131,535.34	1,131,535.34
(5) B	-	1,131,535.34	1,131,535.34
(6) B	-	300,343,934.11	300,343,934.11
2. A			
(1) B	-	112,350,605.05	112,350,605.05
(2) I	-	13,029,069.41	13,029,069.41
(3) D	-	13,029,069.41	13,029,069.41
(4) B	-	500,365.39	500,365.39
(5) B	-	500,365.39	500,365.39
(6) B	-	129,878,808.57	129,878,808.57
3. I	\$ -		
(1) B	-	-	-
(2) I	-	-	-
(3) D	-	-	-
(4) B	-	-	-
4. C			
(1) C	-	170,465,125.54	170,465,125.54
(2) C	-	139,054,506.63	139,054,506.63

Notes to the Financial Statements

F J 30, 2024

(A B)

1. $\nabla \cdot \mathbf{u} = 0$ (incompressibility)

(XV) Intangible assets

	Land use rights	Trademark rights	Software	Medical practice qualifications	Contractual rights to provide management services	Total
1.	\$ -					

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(Amount in million RMB)

1. Goodwill

(XVI) Goodwill

1. Goodwill

Name of the investees or events generating goodwill	Billion RMB	Increase in the current period		Decrease in the current period		Balance as at the end of the period
		Arising from business combination	Increase of provision for goodwill impairment	Disposal	Disposal of goodwill impairment	
	\$ million					
Wenzhou Kangning Hospital Co., Ltd.	9,271,800.00					9,271,800.00
Hangzhou Kangning Hospital Co., Ltd.	690,331.47					690,331.47
Guangzhou Kangning Hospital Co., Ltd.	1,549,022.38					1,549,022.38
Wenzhou Kangning Hospital Co., Ltd. Dalian Branch	7,784,850.00					7,784,850.00
Baotou Kangning Hospital Co., Ltd.	22,987,331.04					22,987,331.04
Hangzhou Kangning Hospital Co., Ltd. Huzhou Branch	151,048.40					151,048.40
Hangzhou Kangning Hospital Co., Ltd. Huzhou Branch	5,068,959.78					5,068,959.78
Chengdu Kangning Hospital Co., Ltd.	6,843,288.91					6,843,288.91
Chengdu Kangning Hospital Co., Ltd. Huzhou Branch	19,416,285.97					19,416,285.97
Chengdu Kangning Hospital Co., Ltd. Huzhou Branch	51,770,194.67					51,770,194.67
Hangzhou Kangning Hospital Co., Ltd. Huzhou Branch	1,272,643.00					1,272,643.00
Jiangsu Kangning Hospital Co., Ltd.	5,060,323.85					5,060,323.85
Chengdu Kangning Hospital Co., Ltd. Huzhou Branch	283,528.10					283,528.10
Dalian Kangning Hospital Co., Ltd.	2,502,854.13					2,502,854.13
Chengdu Kangning Hospital Co., Ltd. Huzhou Branch	9,564,442.65					9,564,442.65
Chengdu Kangning Hospital Co., Ltd. Huzhou Branch	228,538.31					228,538.31
	144,445,442.66					144,445,442.66

Notes to the Financial Statements

For the year ended June 30, 2024

(As presented in the consolidated financial statements)

(XVI) Goodwill (Continued)

The following table shows the carrying amount of goodwill as at the end of the period and the carrying amount as at the end of the prior year.

in B'0,000

Name of goodwill asset groups or portfolio of asset groups	Composition and basis of asset groups or portfolio of asset groups	Carrying amount as at the end of the period	Consistent with the prior years or not
▼ H C, . A	\$ - -	1,342.46	-
H C, . A	\$ - -	1,645.65	-
G H C, . A	\$ - -	1,074.50	-
▼ H C, . A	\$ - -	771.11	-
B H C, . A	\$ - -	4,178.64	-
H C, . A	\$ - -	14.48	-
H H C, . A	\$ - -	552.41	-
C H C, . A	\$ - -	1,278.50	-
C H C, . A	\$ - -	3,726.83	-
▼ C H A	\$ - -	12,548.35	-
H C, . A	\$ - -	181.32	-
J H C, . A	\$ - -	7,011.47	-
C H A	\$ - -	2,485.39	-
D H C, . A	\$ - -	2,179.53	-
C J H C, . A	\$ - -	2,792.84	-
A C, . A	\$ - -	4.09	-
		41,787.57	



Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024

(Amount in thousands of RMB)

1. Long-term prepaid expenses

(XVII) Long-term prepaid expenses

Items	Balance at the beginning of the period	Increase in the current period	Amortisation in the current period	Balance as at the end of the period
	\$			
Prepaid medical insurance	175,706,029.27	1,863,337.07	21,012,423.47	156,556,942.87
Prepaid property taxes	178,292.93	38,000.00	41,641.68	174,651.25
Prepaid water fees	26,303.94		7,316.61	18,987.33
	175,910,626.14	1,901,337.07	21,061,381.76	156,750,581.45

(XVIII) Deferred tax assets and deferred tax liabilities

1. Deferred tax assets and deferred tax liabilities

Items	Balance as at the end of the period		Balance at the beginning of the period	
	Deductible temporary differences	Deferred tax assets	Deductible temporary differences	Deferred tax assets
Prepaid medical insurance	37,735,416.76	7,995,190.93	25,318,013.56	5,221,670.24
Prepaid property taxes	36,307,991.72	9,076,997.93	3,073,067.80	3,073,067.80
Prepaid water fees	94,761,661.96	18,358,697.14	126,627,704.89	26,623,506.01
Prepaid medical insurance	178,203,515.38	44,007,128.21	181,046,756.88	45,261,689.23
Prepaid property taxes	55,456,176.01	8,308,050.85	54,688,502.33	8,203,275.35
	402,464,761.83	87,746,065.06	390,754,045.46	88,388,208.63

Notes to the Financial Statements

F J 30, 2024
(A B)



Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024

(Amount in thousands of RMB)

1. Assets with restricted ownership or right-of-use

(XX) Assets with restricted ownership or right-of-use

Items	As at the end of the period		Types for restriction	Case for restriction	Amount in thousands of RMB		Currency	Unit
	Book balance	Carrying amount			B	C		
Bank acceptance deposit	150,009.00	150,009.00	Guarantee	Bank acceptance deposit	772,510.54	772,510.54	F	B
Performance bond	5,000,000.00	5,000,000.00	Guarantee	Performance bond	12,000,000.00	12,000,000.00	F	F
Foreign Exchange Control Account	1,363,135.53	1,363,135.53	Freezing	Foreign Exchange Control Account	1,361,750.73	1,361,750.73	F	E
					2,120.75	2,120.75	F	C
					2,000.00	2,000.00	F	A
Pledged loans	208,244,700.00	208,244,700.00	Pledge	Pledged loans	208,244,700.00	208,244,700.00		
Sale and leaseback	104,902,010.82	104,902,010.82	Mortgage	Sale and leaseback	101,426,794.17	19,472,320.31	U	
Secured borrowings	215,173,758.25	215,173,758.25	Mortgage	Secured borrowings	161,356,152.45	156,403,844.90	U	
Secured borrowings	26,041,873.00	26,041,873.00	Mortgage	Secured borrowings	59,523,539.00	52,511,079.33	U	
	240,799,717.53	240,799,717.53			281,904,499.27	274,392,040.60		

(XXI) Short-term borrowings

Items	Balance as at the end of the period	B	C
G	111,000,000.00	125,000,000.00	2,001,700.00
	111,000,000.00	127,001,700.00	

Notes to the Financial Statements

F 30, 2024
(A B)

I . (C)

(XXII) Financial liabilities held for trading

	Balance as at the end of the period	B \$
Items		
F	12,400,000.00	12,400,000.00

(XXIII) Accounts payable

	Balance as at the end of the period	B \$
Items		

Notes to the Financial Statements

For the year ended June 30, 2024

(As per the audited financial statements)

1. (C)

(XXVI) Employee benefits payable (Continued)

Items	B \$	Increase in the current period	Decrease in the current period	Balance as at the end of the period
B	4,113,499.45	17,853,475.62	19,109,187.58	2,862,787.49
	141,199.04	593,688.95	648,098.81	86,789.18
	4,259,698.49	18,447,164.57	19,757,286.39	2,949,576.67

1. (C) G

(XXVII) Taxes payable

Items	Balance as at the end of the period	B \$
- (A)	2,694,016.67	3,056,261.74
E	22,926,288.67	30,600,774.99
I \$	1,720,787.95	1,143,039.23
C	104,506.51	134,739.29
	3,012,925.99	2,960,159.04
E	74,789.97	96,590.13
	305,640.50	523,433.13
	13,843.13	31,053.22
E \$	2,094.00	1,369.00
- F	552.42	771.60
	30,855,445.81	33,553,746.47

Balance as at the end of the period	B \$	~
	35,313.43	
2,370,000.00	624,000.00	
66,117,137.05	149,611,261.72	
68,487,137.05	150,270,575.15	

Balance as at the end of the period	B	1
	\$	-
		35,313.43
		35,313.43

	Balance as at the end of the period	B \$	—
	2,370,000.00	624,000.00	
	2,370,000.00	624,000.00	

Notes to the Financial Statements

For the period ended June 30, 2024

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

(XXVIII) Other payables (Continued)

3.

Items	Balance as at the end of the period	B \$
	17,785,659.46	62,637,634.31
	1,313,457.77	1,313,457.77
	1,740,116.45	6,766,360.73
D	1,237,034.24	1,663,762.95
C	29,986,754.10	33,542,529.94
	3,677,029.66	9,345,641.23
A	8,254,225.35	23,431,495.22
	2,122,860.02	360,379.52
	66,117,137.05	149,611,261.72

(XXIX) Non-current liabilities due within one year

Items	Balance as at the end of the period	B \$
	44,136,233.34	130,020,000.00
	41,370,743.00	41,747,363.00
	22,779,404.91	23,643,333.99
	108,286,381.25	250,411,500.00



Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024

(Amount in thousands of RMB)

1. Other current liabilities (C)

(XXX) Other current liabilities

Items	Balance as at the end of the period	B ¥
Accounts payable	5,575.47	
Other payables	563,849.74	
	569,425.21	

(XXXI) Long-term borrowings

Items	Balance as at the end of the period	B ¥
Long-term borrowings	89,166,233.34	212,342,127.25
Guaranteed bank loans	306,620,000.00	252,010,000.00
Other bank loans	416,574,669.65	272,337,037.44
Other long-term borrowings	44,136,233.34	130,020,000.00
	768,224,669.65	557,719,214.69

(XXXII) Lease liabilities

Items	Balance as at the end of the period	B ¥
Lease liabilities	158,912,952.10	163,239,532.76
	158,912,952.10	163,239,532.76

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XXXIII) Long-term accounts payable

Items	Balance as at the end of the period	B \$
-	64,227,913.88	61,351,340.53
	64,227,913.88	61,351,340.53

I : -

Items	Balance as at the end of the period	B \$
F	105,598,656.88	103,099,203.53
I	15,254,200.16	15,109,210.13
	41,370,743.00	41,747,363.00
	64,227,913.88	61,351,340.53

(XXXIV) Deferred income

Items	BB \$	Increase in the current period	Decrease in the current period	Balance as at the end of the period	A \$
G \$	8,734,099.00		151,896.00	8,582,203.00	
	8,734,099.00		151,896.00	8,582,203.00	



Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024

(Amount in thousands of RMB)

1. Capital surplus (XXXVI)

(XXXVI) Capital surplus

Items	Balance at the beginning of the period	Increase in the current period	Decrease in the current period	Balance as at the end of the period
Capital surplus	781,037,804.26		12,709,794.63	768,328,009.63
Capital reserve	44,857,374.20	767,673.68		45,625,047.88
Surplus reserve	26,800,423.23			26,800,423.23
	852,695,601.69	767,673.68	12,709,794.63	840,753,480.74

(XXXVII) Treasury stock

Items	Balance at the beginning of the period	Increase in the current period	Decrease in the current period	Balance as at the end of the period
Treasury stock	12,587,011.74		9,440,179.03	3,146,832.71
	12,587,011.74		9,440,179.03	3,146,832.71

(XXXVIII) Surplus reserve

Items	Balance at the beginning of the period	Increase in the current period	Decrease in the current period	Balance as at the end of the period
Surplus reserve	38,399,577.13			38,399,577.13
	38,399,577.13			38,399,577.13

Notes to the Financial Statements

F 30, 2024
(A B)

(C)

(XXXIX) Retained earnings

Items	Amount for the current period	A \$
	311,956,229.16	233,506,534.43
A	311,956,229.16	233,506,534.43
A	50,723,744.20	35,947,306.64
A		
A		
D \$	22,380,090.00	7,493,111.91
D \$		
	340,299,883.36	311,956,229.16

(XL) Revenue and cost of sales

Items	Revenue	Cost	A \$	C \$
	765,636,198.08	555,217,793.42	723,692,633.43	547,491,901.17
	63,321,355.63	47,582,667.69	49,232,530.41	23,393,694.59
	828,957,553.71	602,800,461.11	777,925,163.84	576,390,595.76

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024
(Amount in million RMB)

1. Revenue and cost of sales (Continued)

1. A -- ¥ \$ -- ¥ -- (C)
B ¥ \$:

Items	Amount for the current period	A ¥
\$ ¥ -- --	765,636,198.08	725,692,633.43
\$ ¥ -- -- \$ --	765,636,198.08	725,692,633.43
\$ ¥ -- -- \$ ¥	63,321,355.63	49,232,530.41
¥	41,715,643.36	25,551,507.57
¥ -- \$ --	7,958,001.19	1,455,145.50
	297,619.53	2,557,971.77
	13,350,091.55	16,007,602.57
	828,957,553.71	777,925,163.54

2. D -- ¥ ¥ -- --

Items	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
	A --		D --			
¥ \$ --	¥ \$ --	B --		¥ \$ --	¥	¥

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XLI) Taxes and charges

Items	Amount for the current period	A \$
	4,886,926.23	1,704,919.27
C	460,954.07	393,619.06
E	331,720.92	234,361.36
	445,099.29	244,223.99
	130,348.60	139,457.31
	13,249.84	11,774.66
	6,268,298.95	2,733,361.65

(XLII) Selling and distribution expenses

Items	Amount for the current period	A \$
E	5,264,561.40	4,571,354.43
D	99,249.43	96,371.30
A	21,787.27	22,513.69
A	155,095.54	155,131.63
E	435,531.57	316,393.31
	316,961.17	130,167.93
	179,730.55	167,234.65
		10,473.13
	219,294.83	235,341.00
	2,388,776.86	2,020,072.51
	139,038.00	25,263.40
	29,239.82	27,732.42
	9,249,266.44	7,323,610.00

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024

(Amount in thousands of RMB)

1. General and administrative expenses

(XIII) General and administrative expenses

Items	Amount for the current period	A
Salaries and wages	63,615,210.18	55,921,762.53
Debt interest	7,553,031.91	6,990,039.75
Administrative fees	1,874,457.13	1,300,111.04
Administrative fees	4,527,100.72	4,634,159.30
Depreciation and amortization	963,471.75	1,039,347.77
Heating	1,323,759.68	1,336,037.33
Transportation	767,673.68	
Travel	2,276,602.65	1,700,201.12
Office expenses	2,198,731.91	2,070,523.66
Advertising	351,396.86	717,753.37
Research and development	2,919,344.90	1,676,255.06
Consulting	1,024,421.20	1,263,793.76
Professional fees	1,308,692.84	1,532,961.73
Commission	1,815,859.33	14,377,209.14
Advertising	2,226,500.13	
Transportation	5,421,178.66	3,243,243.19
Entertainment	2,803,324.36	2,599,553.04
Other	3,300,625.81	366,013.32
	106,271,383.70	101,924,026.76

(XIV) Research and development expenses

Items	Amount for the current period	A
Salaries and wages	17,015,841.55	13,993,396.69
Debt interest	313,121.72	191,563.31
Administrative fees	23,806.46	92,076.43
Office expenses	1,279.22	1,369.72
Transportation	7,292.41	333,933.66
Entertainment	7,536.00	
Other	219,198.79	235,100.27
	17,588,076.15	14,957,995.63

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(XLV) Financial expenses

Items	Amount for the current period	A \$
	23,323,466.98	19,132,137.46
	5,245,075.86	5,053,106.16
	2,686,209.46	2,704,331.09
F	99,244.67	-13,070.04
	3,728,948.96	3,695,397.63
	24,465,451.15	20,159,633.96

(XLVI) Other income

Items	Amount for the current period	A \$
G \$	5,386,176.18	5,600,421.10
A A	13,945.83	200,405.44
F \$	188,141.27	21,663.61
	5,588,263.28	5,822,495.15

(XLVII) Investment income

Items	Amount for the current period	A \$
	478,827.96	-157,522.45
	1,201,371.61	-33,203.43
	1,680,199.57	-195,725.93

Notes to the Financial Statements

F 30, 2024
(A B)

1 (C)

(XLVIII) Gain from change in fair value

Source of gains from changes in fair value	Amount for the current period	A	¥
		\$	-
F	248,879.60		
-	-347,402.79		
	-98,523.19		

(XLIX) Credit impairment losses

Items	Amount for the current period	A	¥
		\$	-

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(Amount in million RMB unless otherwise specified)

1. Income tax expenses

(LIII) Income tax expenses

1. Current income tax expenses

Items	Amount for the current period	Amount for the current period
Cash	19,082,552.41	23,358,206.57
Debt	-2,566,409.06	-11,880,326.50
	16,516,143.35	11,477,880.07

2. Deferred income tax expenses

Items	Amount for the current period
Income tax expense	61,512,576.64
Income tax expense	12,647,013.90
Income tax expense	474,180.04
Income tax expense	-769,492.74
Income tax expense	817,638.14
Income tax expense	-4,610,218.14
Income tax expense	9,615,739.59
Income tax expense	-3,065,849.16
Income tax expense	1,407,131.72
Income tax expense	16,516,143.35

Notes to the Financial Statements

F J 30, 2024
(A B)

| .

Supplementary information					Amount for the current period	A	Δ
					\$	-	
1.		Δ	Δ	- Δ	Δ		
					\$ -		
	Δ						
					44,996,433.29		43,750,057.46
	A : C						057.46

F J 30, 2024

$$| \cdot |_{\mathcal{C}} = \frac{1}{2} \left(| \cdot |_{\mathcal{C}_1} + | \cdot |_{\mathcal{C}_2} \right)$$
$$1. \quad \downarrow \quad \quad \quad \downarrow \quad \quad \quad \downarrow \quad \quad \quad \downarrow \quad \quad \quad (C)$$

Items	Balance as at the end of the period	B \$
I. C	366,789,288.94	262,363,904.62
I : C	315,188.51	209,153.36
C	365,833,425.73	262,235,513.11
	640,674.70	424,203.15
II. C		
I : B		
III. C	366,789,288.94	262,363,904.62
I : C		

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(All amounts in RMB, unless otherwise specified)

Name of subsidiary	Disposal price at the date of loss of control	Disposal at the date of loss of control	Basis for determining the date of loss of control	Difference between the consideration for disposal and the share of net assets of the subsidiary at the level of the relevant consolidated financial statements	
				as of the date of consolidated loss of control	as of the date of consolidated loss of control
(I) Disposal of subsidiaries					
1.					

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(Amount in million RMB, unless otherwise specified)

Name of Subsidiary	Type of legal entity	Registered capital (RMB'0,000)	Major business location	Place of registration	Nature of business	Shareholding (%)		Method of acquisition
						Direct	Indirect	
Hong Kong Kangning Hospital Co., Ltd.	C	2,040.92	H	H	Medical services	-	99.00	I
Donghai Kangning Hospital Co., Ltd.	C	50.00			Dental services		100.00	I
Shanghai Kangning Hospital Co., Ltd.	C	500.00			Hospital management		100.00	I
Donghai Kangning Hospital Co., Ltd.	C	1,000.00			Medical services		99.00	I
Chongqing Kangning Hospital Co., Ltd.	C	2,200.00	C	C	Medical services	64.55		C
Hong Kong Kangning Hospital Co., Ltd.	C	500.00	H	H	Medical services		100.00	I
Hong Kong Kangning Hospital Co., Ltd.	C	100.00	H	H	Medical services		100.00	I
Chongqing Kangning Hospital Co., Ltd.	C	5,000.00			Medical services		100.00	I
Hong Kong Kangning Hospital Co., Ltd.	C	6,000.00			Medical services		55.00	I
Hong Kong Kangning Hospital Co., Ltd.								

Notes to the Financial Statements

For the year ended 30 June 2024
(Amount in million US dollars)

1. Interests in subsidiaries (Continued)

(I) Interests in subsidiaries (Continued)

1. Subsidiaries (Continued)

Name of Subsidiary	Type of legal entity	Registered capital (RMB'0,000)	Major business location	Place of registration	Nature of business	Shareholding (%)		Method of acquisition
						Direct	Indirect	
1. C H	C	3,057.47			W - \$	100.00		C
2. I C	C	9,900.00			W - \$	100.00		C
J H C	C	2,399.26	J	J	W - \$	55.00		C
C H C	C	1,940.00			W - \$	51.00		C
3. H C	C	3,000.00			W - \$		100.00	I
A C	C	100.00			D		100.00	C
D H C	C	1,900.00			W - \$	51.00		C
C C	C	50.00			W - \$	100.00		I
J J C	C	6,001.00	J	J	\$ -	66.60	33.30	I
C J C	C	2,099.33	C	C	W - \$		49.33	C
G F H C	C	1,000.00			W - \$		100.00	I
G H	C	20,000.00			W	100.00		I

E

A

G H

100%.

(I) Interests in subsidiaries (Continued)

Name of Subsidiary	Shareholding percentage of non-controlling shareholder	Current profits or losses attributable to non-controlling shareholders	Current dividends distributed to non-controlling shareholders	Closing balance of interest of non-controlling shareholders
Hong Kong China Water Supply Co., Ltd.	40.00%	44,636.00		30,411,626.36
Japan Water Supply Co., Ltd.	45.00%	-1,622,191.24		16,064,103.54

F J 30, 2024

$$(A \quad \begin{array}{c} \nearrow \\ \searrow \end{array} \quad B \quad \begin{array}{cc} \nearrow & \searrow \\ \nearrow & \searrow \end{array})$$

(II) Transactions that cause changes in the s

$$1 \rightarrow E \rightarrow \pi_1(\Sigma) \xrightarrow{f} \pi_1(\Sigma) \rightarrow \pi_1(\Sigma) \rightarrow \pi_1(\Sigma)$$

E
 I F 2024, B
 H C , , C
 B A I \$ ()
 B0.3 B1
 B15,300,000.00.
 B H C B46,536,700.00,
 C 51% 67.77%.
 A \$ -
 C
 B3,375,411.44,
 \$ ()

1 M \$ - - -

Name of joint venture or associate	Major business location	Place of registration	Nature of business	Shareholding (%)		Accounting method for investment in joint ventures or associates	Whether strategic to the Company's activities or not
				Direct	Indirect		
China Huijin Investment Co., Ltd.	China	China	Investment holding	45.00	-	Equity method	Yes
China Huijin Investment Co., Ltd.	China	China	Investment holding	-	30.00	Equity method	Yes

(III) Interests in joint arrangements or associations

Notes to the Financial Statements

F J 30, 2024

$$(A \quad \begin{smallmatrix} \nearrow & \searrow \\ \nearrow & \searrow \end{smallmatrix} B \quad \begin{smallmatrix} \nearrow & \searrow \\ \nearrow & \searrow \end{smallmatrix} \quad \begin{smallmatrix} \nearrow & \searrow \\ \nearrow & \searrow \end{smallmatrix})$$

II.

(I) Various risks associated with financial instruments

[illegible]

C

1. C

C

C

C

C

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(Amount in million RMB unless otherwise specified)

II. Significant accounting estimates and assumptions (Continued)

(I) Various risks associated with financial instruments (Continued)

1. Credit risk (Continued)

Credit risk is the risk that one or more counterparties will fail to meet their contractual obligations, resulting in financial loss. The Company's credit risk is primarily concentrated in the receivables from customers, which are classified into various categories based on the nature of the goods sold and the credit terms. The Company has established a credit management system to monitor and control the credit risk. The Company's credit risk is primarily concentrated in the receivables from customers, which are classified into various categories based on the nature of the goods sold and the credit terms. The Company has established a credit management system to monitor and control the credit risk. The Company's credit risk is primarily concentrated in the receivables from customers, which are classified into various categories based on the nature of the goods sold and the credit terms. The Company has established a credit management system to monitor and control the credit risk.

2.

The Company's credit risk is primarily concentrated in the receivables from customers, which are classified into various categories based on the nature of the goods sold and the credit terms. The Company has established a credit management system to monitor and control the credit risk. The Company's credit risk is primarily concentrated in the receivables from customers, which are classified into various categories based on the nature of the goods sold and the credit terms. The Company has established a credit management system to monitor and control the credit risk.

Notes to the Financial Statements

For the year ended 30, 2024

(As at 30, 2024)

II. Various risks associated with financial instruments (Continued)

(I) Various risks associated with financial instruments (Continued)

2. Credit risk

Items	Closing balance					Total undiscounted contract amount	Book value
	Instant repayment	Within 1 year	1-2 years	2-5 years	Over 5 years		
A		112,544,938.03				112,544,938.03	112,544,938.03
B		68,487,137.05				68,487,137.05	68,487,137.05
C		111,000,000.00				111,000,000.00	111,000,000.00
D		108,286,381.25				108,286,381.25	108,286,381.25
E			287,545,000.00	314,094,120.00	166,585,549.65	768,224,669.65	768,224,669.65
F			18,133,866.38	54,983,512.27	95,622,594.14	168,739,972.79	158,912,952.10
G			25,945,947.15	45,352,431.95		71,298,379.10	64,227,913.88
H		400,318,456.33	331,624,813.53	414,430,064.22	262,208,143.79	1,408,581,477.87	1,210,651,916.88

B 10,143,732.40 83,023 \$ 5,227.56 3

10,143,732.40 83,023 \$ 5,227.56 3

1

1

1

Notes to the Financial Statements

For the period ended June 30, 2024
(Amounts in US\$ millions)

II. Financial Instruments (Continued)

(I) Various risks associated with financial instruments (Continued)

3. Foreign currency risk (Continued)

(2) Foreign currency risk																											
Foreign currency risk arises from the use of currencies other than the functional currency of the Company in its operations. The Company's financial statements are presented in US dollars. The Company's functional currency is the US dollar. The Company's operations are conducted in various currencies, including the US dollar, the Chinese renminbi, and the Hong Kong dollar. The Company's foreign currency risk is managed through a variety of instruments, including foreign exchange contracts, forward contracts, and options.																											
The following table summarizes the Company's foreign currency risk exposure as of June 30, 2024:																											
<table border="1"> <thead> <tr> <th>Items</th><th>US\$</th><th>Other foreign currencies</th><th>Total</th><th>US\$</th><th>Other foreign currencies</th><th>Total</th></tr> </thead> <tbody> <tr> <td>Cash and cash equivalents</td><td>285,090.74</td><td>45,278.51</td><td>330,369.25</td><td>31,905.11</td><td>52,061.43</td><td>133,966.54</td></tr> <tr> <td>Accounts receivable</td><td>285,090.74</td><td>45,278.51</td><td>330,369.25</td><td>31,905.11</td><td>52,061.43</td><td>133,966.54</td></tr> </tbody> </table>							Items	US\$	Other foreign currencies	Total	US\$	Other foreign currencies	Total	Cash and cash equivalents	285,090.74	45,278.51	330,369.25	31,905.11	52,061.43	133,966.54	Accounts receivable	285,090.74	45,278.51	330,369.25	31,905.11	52,061.43	133,966.54
Items	US\$	Other foreign currencies	Total	US\$	Other foreign currencies	Total																					
Cash and cash equivalents	285,090.74	45,278.51	330,369.25	31,905.11	52,061.43	133,966.54																					
Accounts receivable	285,090.74	45,278.51	330,369.25	31,905.11	52,061.43	133,966.54																					
Closing balance																											
Other foreign currencies																											

As of June 30, 2024, the Company's foreign currency risk exposure was \$133,966.54 million. The Company's foreign currency risk is managed through a variety of instruments, including foreign exchange contracts, forward contracts, and options. The Company's foreign currency risk is managed through a variety of instruments, including foreign exchange contracts, forward contracts, and options. The Company's foreign currency risk is managed through a variety of instruments, including foreign exchange contracts, forward contracts, and options.

Notes to the Financial Statements

F 30, 2024

(A B)

III. D \$ (C)

(I) Closing fair value of assets and liabilities measured at fair value

Items	Closing fair value			Total
	Measured at fair value at Level 1	Measured at fair value at Level 2	Measured at fair value at Level 3	
I. Continuous measurement of fair value				
F			7,599,173.13	7,599,173.13
1. F			7,599,173.13	7,599,173.13
(1)	\$			
(2)	\$		7,599,173.13	7,599,173.13
2. F				
\$				
-			64,751,652.55	64,751,652.55
1. F			64,751,652.55	64,751,652.55
(1)	\$			
(2)	\$		64,751,652.55	64,751,652.55
Total assets with continuous measurement of fair value			72,350,830.68	72,350,830.68
F			12,400,000.00	12,400,000.00
1. F			12,400,000.00	12,400,000.00
(1) E				
(2) D	\$	\$		
(3)			12,400,000.00	12,400,000.00
2. F				
\$				
Total liabilities with continuous measurement of fair value			12,400,000.00	12,400,000.00

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024

(Amount in million RMB Yuan, unless otherwise specified)

III. Derivative Financial Instruments

- (II) Qualitative and quantitative information of valuation techniques and key parameters adopted for items measured at the fair value of level 3 on a going and non-going concern

1.

At the end of the reporting period, the Company has entered into the following derivative financial instruments:

Item	Contract Amount (million RMB)	Notional Amount (million RMB)	Contract Period	Contract Counterparty	Contract Type	Contract Purpose
1.1	100	100	2024.01.01-2024.12.31	Bank of China	Interest Rate Swap	Interest Rate Risk Management
2.

At the end of the reporting period, the Company has entered into the following derivative financial instruments:

Item	Contract Amount (million RMB)	Notional Amount (million RMB)	Contract Period	Contract Counterparty	Contract Type	Contract Purpose
2.1	100	100	2024.01.01-2024.12.31	Bank of China	Interest Rate Swap	Interest Rate Risk Management

Notes to the Financial Statements

F J 30, 2024
(A B)

| .

Notes to the Financial Statements

F 30, 2024
(A B)

1 (C)

(IV) Information of other related parties

Name of other related parties	Other related parties' relationship with the Company			
C				C
C G				C
J D				C
W B A				C
I \$ M				
()				
(寧波梅山保稅港區寬展投資管理合夥企業(有限合夥))				
F H M C , .				C
H				C
				C
				C
				C
H C , .				C
(四川省宏濟藥業有限責任公司)				
C				
M H C				C
E \$ C C , .				C
M C , .				C
H H C , .				C
A C C , .				C
H C , .				C

Notes to the Financial Statements

F J 30, 2024

(A)  (B)  (C)  (D) 

$$| \cdot |_{\infty} = \| \cdot \|_{\infty}(C)$$

(V) Information on related party transactions

1. $\frac{1}{2} \times \frac{1}{2} = \frac{1}{4}$ $\frac{1}{4} \times \frac{1}{4} = \frac{1}{16}$ $\frac{1}{16} \times \frac{1}{16} = \frac{1}{256}$ $\frac{1}{256} \times \frac{1}{256} = \frac{1}{65536}$ $\frac{1}{65536} \times \frac{1}{65536} = \frac{1}{4294967296}$

$$\frac{1}{2} = \frac{1}{2} \quad \frac{1}{2} = \frac{1}{2} \quad \frac{1}{2} = \frac{1}{2} \quad \frac{1}{2} = \frac{1}{2} \quad \frac{1}{2} = \frac{1}{2}$$

Related party	Amount for the period	A	U.S. dollars
Farmington, Inc.	46,490.62		
Atlantic City, Inc.	17,960.18		

$$\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & -i \\ 0 & 1 \end{pmatrix} = \frac{1}{\sqrt{2}} \begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix} - \frac{i}{\sqrt{2}} \begin{pmatrix} 0 & 1 \\ 1 & 0 \end{pmatrix}$$
[illegible]

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024
(Amount in million RMB)

1. Information on related party transactions (Continued)

(V) Information on related party transactions (Continued)

2. Guarantees provided by the Company

Cash and cash equivalents

Name of guaranteed party	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
H - C	14,660,000.00	2019/9/10	2029/9/20	✓
H - C	10,250,000.00	2020/1/1	2029/9/20	✓
H - C	3,320,000.00	2020/12/22	2029/9/20	✓
H - C	2,200,000.00	2020/9/27	2029/9/20	✓
H - C	2,200,000.00	2020/9/27	2029/9/20	✓
H - C	3,050,000.00	2021/3/1	2029/9/20	✓
H - C	3,050,000.00	2021/3/1	2029/9/20	✓
H - C	45,000,000.00	2023/7/3	2037/12/31	✓
H - C	15,000,000.00	2023/7/31	2037/12/31	✓
H - C	10,116,550.00	2023/10/25	2037/12/31	✓
H - C	5,007,200.00	2023/11/24	2037/12/31	✓
H - C	5,000,000.00	2020/3/25	2024/12/20	✓
H - C	17,500,000.00	2020/5/22	2024/12/20	✓
H - C	60,000,000.00	2023/10/9	2031/10/9	✓
H - C	2,000,000.00	2023/3/31	2024/3/29	-
C H - C	26,000,000.00	2023/4/3	2032/3/2	✓

Notes to the Financial Statements

For the year ended 30, 2024

(Audited by the Board of Directors)

1. Information on related party transactions (Continued)

(V) Information on related party transactions (Continued)

2. Information on related party transactions (Continued)

Name of guarantor	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
Hong Kong & Shanghai	200,000,000.00		2026/12/24	▼
Hong Kong & Shanghai	200,000,000.00		2026/12/24	▼
C Hong Kong & Shanghai	200,000,000.00		2026/12/24	▼
C Hong Kong & Shanghai	66,474,000.00		2026/12/10	▼
Hong Kong & Shanghai	200,000,000.00		2026/12/24	▼
G ,	24,000,000.00	2020/6/30	2027/6/30	▼
G , H ,	79,642,127.25	2021/11/29	2028/11/29	▼
G , H ,	130,950,000.00	2020/10/26	2026/10/25	▼
G ,	70,000,000.00	2023/11/15	2026/11/15	▼
G ,	135,000,000.00	2023/12/14	2024/12/14	▼
G , , H	14,660,000.00	2019/9/10	2029/9/20	▼
G , , H	10,250,000.00	2020/1/1	2029/9/20	▼
G , , H	3,320,000.00	2020/12/22	2029/9/20	▼
G , , H	2,200,000.00	2020/9/27	2029/9/20	▼
G , , H	2,200,000.00	2020/9/27	2029/9/20	▼
G , , H	3,050,000.00	2021/3/1	2029/9/20	▼
G , , H	3,050,000.00	2021/3/1	2029/9/20	▼
G , , H	45,000,000.00	2023/7/3	2037/12/31	▼
G , , H	15,000,000.00	2023/7/31	2037/12/31	▼
G , , H	10,116,550.00	2023/10/25	2037/12/31	▼
G , , H	5,007,200.00	2023/11/24	2037/12/31	▼
G , , H	5,000,000.00	2020/3/25	2024/12/20	▼
G , , H	17,500,000.00	2020/5/22	2024/12/20	▼
G , E \$				▼
C Hong Kong & Shanghai	60,000,000.00	2023/10/9	2031/10/9	▼

Notes to the Financial Statements

F 30, 2024

(A B)

I . (C)

(VI) Receivables from and payables to related parties and other unsettled items

1. \$.

Items	Related parties	Balance as at the end of the period		B	
		Book balance	Provision for bad debts	B	
A					
	H				
	H C .			65,000.00	3,250.00
	H A				
	C .	1,522.85	15.23	1,522.85	15.23
	H	635,000.00	6,350.00	635,000.00	6,350.00
	H				
	H C .	23,066,977.13	23,066,977.13	34,005,471.02	1,700,273.55
	H				
	C .	13,903,890.41	695,194.52	14,290,027.40	714,501.37
	H				
	C .	10,204,311.69	10,204,311.69	10,204,311.69	10,204,311.69
	C	3,490,447.08	3,490,447.08	3,490,447.08	3,490,447.08
	H A				
	C .	16,836.66	841.83	16,836.66	841.83
	C G	100,000.00	1,000.00	100,000.00	1,000.00
		80,004.00	800.04	80,004.00	800.04
	C	75,187.50	3,759.38	105,187.50	5,259.38
	J D	431,587.50	21,579.38	479,707.50	23,959.38

Notes to the Financial Statements

F 2024 J 30, 2024
(A 2024 B 2024)

1. (C)

(VI) Receivables from and payables to related parties and other unsettled items (Continued)

2. 2024

		B 2024	
		Book balance as at the end of the period	
Items	Related parties		\$

Notes to the Financial Statements

F J 30, 2024
(A B)

I . (C)

(VII) Five Individuals with Highest Remunerations

F J J 2024, \$ \$ (J J 2023: 0), \$ C \$

Items Amount for
Totalble:

(I) Summary of share-based payment

 $\gamma = \frac{1}{\sqrt{1 - \beta^2}}$ C :

1.  / 

J 13, 2013, C 2013, B 2013, \$
 C H E 2013, B
 C B C \$
 G J 29, 2013 A
 20, 2013, C
 I \$ M
 I \$ M
 I \$ M
 I \$ M
 I \$ M
 I \$ M
 (2,460,000
 B10.47 A D 31, 2021,
 \$ \$
 C

F J 30, 2024

(A)  (B)  (C)  (D) 

(C)

(I) Summary of share-based payment (Continued)

2. H A $\rightarrow$

[illegible]

I am not a financial advisor and do not intend to provide any investment advice. The information provided is for informational purposes only and should not be used as a basis for investment decisions. Please consult with a qualified financial advisor for more information.



- **Stressors**
- **Stressors**

Notes to the Financial Statements

F
(A

I. C

(I) Significant commitments

1. C

	June 30, 2024	D	June 31, 2023
H	55,890,951.92		122,040,000.00
	55,890,951.92		122,040,000.00

2. \$

A J 30, 2024, C \$

(II) Contingencies

C

II. E\$

(I) Profit distribution

B

2024

C

B

(

1.50 (\$) 10

(I) Segment Information(I)E  C

Notes to the Financial Statements

F 30, 2024

(A B)



(I) Accounts receivable

1. A \$

	Balance as at the end of the period	B \$
Aging		
1	51,071,471.71	48,552,078.47
1-2	11,406,851.48	257,315.13
2-3	257,315.13	709,878.26
\$ 3	4,616,400.13	3,906,521.87
	67,352,038.45	53,425,793.73
\$	11,362,291.77	5,359,236.04
	55,989,746.68	48,066,557.69

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024
(Amount in thousands of RMB)

Notes to the Financial Statements
(Continued)

(I) Accounts receivable (Continued)

2. Accounts receivable									
Balance as at the end of the period					B				
Book balance					B				
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Carrying amount	A	(%)	A	C
1. Single accounts receivable	4,873,715.26	7.24	4,873,715.26	100.00	4,873,715.26	9.12	4,873,715.26	100.00	
2. Accounts receivable due from related parties	4,873,715.26	7.24	4,873,715.26	100.00	4,873,715.26	9.12	4,873,715.26	100.00	
3. Accounts receivable due from non-related parties	57,018,962.00	92.76	6,488,576.51	11.38	50,530,385.49	49.88	49,520.79	1.00	49,066,557.69
4. Accounts receivable due from government departments	5,459,361.19	8.11			5,459,361.19				
5. Accounts receivable due from other parties	57,018,962.00	84.66	6,488,576.51	11.38	50,530,385.49	49.88	49,520.79	1.00	49,066,557.69
	67,352,038.45	100.00	11,362,291.77		55,989,746.68	53,425,793.73	100.00	5,359,236.04	49,066,557.69
3. Accounts receivable due from related parties									
Balance as at the end of the period					B				
Book balance					B				
Items	Amount	Provision for bad debts	Proportion of provision (%)	Reason for the provision	B				
1. Not expect to be recoverable	4,873,715.26	4,873,715.26	100.00		4,873,715.26		4,873,715.26		
	4,873,715.26	4,873,715.26			4,873,715.26		4,873,715.26		

Notes to the Financial Statements

For the year ended 30, 2024

(Amount in US\$ millions)

(C)

(I) Accounts receivable (Continued)

2. A

Items	Balance as at the end of the period		
	Accounts receivable	Provision for bad debt	Proportion of provision (%)
\$	57,018,962.00	6,488,576.51	11.38
	57,018,962.00	6,488,576.51	

3. A

Category	B	Changes in the current period			Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	
	\$				
	4,873,715.26				4,873,715.26
	4,873,715.26	6,003,055.73			6,488,576.51
	5,359,236.04	6,003,055.73			11,362,291.77

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024
(Amount in million RMB unless otherwise specified)

(C)

(II) Other receivables

Items	Balance as at the end of the period	B \$
1. Other receivables	787,500.00	-
D. Other receivables	14,400,000.00	14,400,000.00
	607,735,083.60	536,043,325.53
	622,922,583.60	600,443,325.53

1. Other receivables

Items	Balance as at the end of the period	B \$
Other receivables	787,500.00	-
	787,500.00	-

2. Other receivables

Item (or investee)	Balance as at the end of the period	B \$
C. Other receivables	4,400,000.00	4,400,000.00
H. Other receivables	10,000,000.00	10,000,000.00
	14,400,000.00	14,400,000.00

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(II) Other receivables (Continued)

3. \$

(1) D

Aging	Balance as at the end of the period	B \$
1	571,062,190.36	552,353,723.97
1 2	5,089,808.65	34,594,797.65
2 3	33,287,580.41	496,167.22
\$ 3	1,158,794.57	903,479.96
	610,598,373.99	533,353,173.80
\$	2,863,290.39	2,304,343.22
	607,735,083.60	536,043,325.53

(2) D

Category	Balance as at the end of the period					B				
	Book balance		Provision for bad debts		Book value	B		B		
	Amount	Proportion (%)	Amount	Proportion of provision (%)		A	(%)	A	(%)	
	610,598,373.99	100.00	2,863,290.39	0.47	607,735,083.60	533,353,173.80	100.00	2,304,343.22	0.43	
A	80,464,046.88	13.18	2,863,290.39	3.56	77,600,756.49	75,462,763.59	12.92	2,304,343.22	3.72	
	530,134,327.11	86.82			530,134,327.11	513,390,405.21				
	610,598,373.99	100.00	2,863,290.39	/	607,735,083.60	533,353,173.80	100.00	2,304,343.22	/	

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(Amount in million RMB unless otherwise specified)

As of June 30, 2024, the Company's other receivables were RMB 610,598,373.99, of which RMB 530,134,327.11 were due within one year and RMB 80,464,046.88 were due after one year.

(II) Other receivables (Continued)

3. Other receivables (Continued)

(2) Details of other receivables: As of June 30, 2024, the Company's other receivables were RMB 610,598,373.99, of which RMB 530,134,327.11 were due within one year and RMB 80,464,046.88 were due after one year.

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
A	80,464,046.88	2,863,290.39	3.56
A	530,134,327.11		
	610,598,373.99	2,863,290.39	

Notes to the Financial Statements

F J 30, 2024

(A $\rightarrow$ B $\rightarrow$)

$$\nabla(C) = \left(\frac{C}{\sqrt{C^2 + 1}}, -\frac{C}{\sqrt{C^2 + 1}}, \frac{C}{\sqrt{C^2 + 1}} \right)$$

(II) Other receivables (Continued)

3. $\$ \quad \neg(C \quad)$

(3) $D = \int \delta = \int \dots$

			Stage I	Stage II	Stage III	
				Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	Total
Provision for bad debts			12-month ECL			
B	\$ -	\$ -				
	\$ -	\$ -	2,804,343.22			2,804,343.22
B	\$ -	\$ -				
	\$ -	\$ -				
-	\$ -	\$ -				
	\$ -	\$ -				
-	\$ -	\$ -				
-	\$ -	\$ -				
\$ -	\$ -	\$ -	53,442.17			53,442.17
\$ -	\$ -	\$ -				
	\$ -	\$ -				
	\$ -	\$ -				
B	\$ -	\$ -	2,863,290.39			2,863,290.39

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024

(Amount in thousands of RMB)

Other receivables (Continued)

(II) Other receivables (Continued)

3. Other receivables (Continued)

(3) Details of other receivables (Continued)

Other receivables (Continued)

		Stage I	Stage II	Stage III	Total
			Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
B	12-month ECL				
B					
	\$ -	588,853,173.80			588,853,173.80
B					
	1 / \$ -				
	II				
	III				
	II				
	I				
A		21,745,200.19			21,745,200.19
D					
B		610,598,373.99			610,598,373.99

Notes to the Financial Statements

For the year ended June 30, 2024

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

(C)

(II) Other receivables (Continued)

3. (C)

(4) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

Category	B	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
	\$					
	2,804,848.22	58,442.17				2,863,290.39
	2,804,848.22	58,442.17				2,863,290.39

(5) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

Nature of receivables	Book balance as at the end of the period	B
		\$
A	530,134,327.11	513,390,405.21
	25,957,550.96	20,480,175.04
D	5,716,830.00	5,920,030.00
	181,832.86	767,065.13
A	48,607,833.06	48,295,498.42
	610,598,373.99	588,853,173.80

Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024
(Amount in million RMB unless otherwise specified)

(Continued)

(III) Long-term equity investments

Items	Balance as at the end of the period			Billion RMB	
	Book balance	Provision for impairment	Book value	2024	2023
Long-term equity investments	698,830,684.03	-	698,830,684.03	691,561,513.66	691,561,513.66
Long-term equity investments	94,549,945.13	-	94,549,945.13	94,421,925.51	94,421,925.51

Notes to the Financial Statements

F 30, 2024
(A B)

(III) Long-term equity investments (Continued)

1. / \$	Increase/decrease in the current period				
	B	Decrease in investment	Provision for impairment for the current period	Balance as at the end of the period	Balance of the impairment provision as at the end of the period
Investees					
H C ,	15,500,000.00			15,500,000.00	
F I	500,000.00			500,000.00	
C ,	204,666,253.57			204,709,938.51	
C	52,697,737.50			52,697,737.50	
H C ,	2,133,258.38			2,133,258.38	
H C ,	27,687,093.11			27,687,093.11	
H C ,	32,856,644.25			32,856,644.25	
H C ,	4,799,071.39			4,799,071.39	
C H C ,	53,515,660.04			53,515,660.04	
H C ,	40,000,000.00	7,200,000.00		48,000,000.00	
H C ,	10,000,000.00			10,000,000.00	
C ,	154,744,700.00			154,750,253.65	
J H C ,	29,051,800.00			29,051,800.00	
H C ,	40,954,955.16			40,954,955.16	
D H C ,	14,510,000.00			14,510,000.00	
C C ,	500,000.00			500,000.00	
J J I \$	6,660,000.00			6,660,000.00	
	691,561,513.66	7,200,000.00		69,170.37	698,830,684.03

Notes to the Financial Statements

F J 30, 2024
(A B)

(III) Long-term equity investments (Continued)

		Increase/decrease in the current period						Balance of the impairment provision as at the end of the period
								Balance as at the end of the period
								Others
								of the period

Notes to the Financial Statements

For the period ended June 30, 2024

(Amounts in millions of US dollars)

(C)

(IV) Revenue and cost of sales

1. Revenue and cost of sales

Items	Amount for the current period		A	
	Revenue	Cost	\$	C
Revenue	185,247,902.83	130,785,130.41	174,575,542.75	130,785,130.41
Cost of sales	7,845,218.13		1,629,256.25	
	193,093,120.96	130,785,130.41	176,204,799.00	130,785,130.41

B

Items	Amount for the current period		A	
			\$	C
Revenue	185,247,902.83		174,575,542.75	
Cost of sales	185,247,902.83		174,575,542.75	
Revenue	7,845,218.13		1,629,256.25	
Cost of sales	6,472,852.67			
	209,955.19		512,200.25	
	1,162,410.27		1,117,055.97	
	193,093,120.96		176,204,799.00	

2. Discontinued operations

Item	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
	A	B	D			
	\$	\$	\$			

Amount for the current period	A	↓
	\$	-
14,061,318.98		
128,019.62	\$16,165.55	
	-1,591,713.27	
14,189,338.60	-775,547.72	

A C
B H B H C . (北京怡寧醫院有限公司),
C A 17, 2015, C
B D B C
C H C H C . (蒼南康寧醫院有限公司) A 2 -
.5 J A.5 ()0.2 (A 17, 2015, 9EB 536 C) J31.952 0.053 (') -32.174 -1.5 (2 008
B 1 D

H	H	H	H	C	., . (淮南康寧醫院有限公司), 22, 2017, C
I	\$	(-)		D	I \$
J	H	J	H	C	., . (縉雲舒寧醫院有限公司), 15, 2019, C
	H		H	C	., . (龍泉康寧醫院有限公司), 6, 2023, C
	H		H	C	., . (婁底市康樂康寧醫院有限責任公司), 23, 2017, C
	H		H	C	., . (溫州鹿城怡寧醫院有限公司), 2, 2020, C
C	H	C	H	C	., . (臨海慈寧醫院有限公司), 11, 2020, C
	H		H	C	., . (南京怡寧醫院有限公司), 22, 2018, C
M			A	\$	C

C
B
F
(
D
H
C
H
C
22, 2014,

033905CB0FB 3.05C3100 0 4 4 0.39 -0.053 () -14 -0.04 1() 0.037 0.0 (

